NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/17/2024
Back to search
Official data from USPTO
LIVERTY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
05/17/2024
Trademark type
Word
Nice classes
5
Filing date
11/15/2012
Registration date
04/08/2014
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/17/2024
Last transaction
05/17/2024
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/30/2013
First use in commerce
07/30/2013
Drawing code
4
Owner type
03
Owner location
New Taipei City, TW
Examiner
SPARER, ZACHARY R
Law office
M60
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
G. C. (pessoa física)
Representatives
Joe McKinney Muncy Muncy, Geissler, Olds & Lowe, P.C
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Adjuvants for medical purposes; antiallergic medicines; anti-cancer preparations; medicinal herbal extracts for medical purposes; pharmaceutical and medicinal preparations and substances for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; pharmaceutical and medicinal preparations for the treatment of brain diseases or disorders and autoimmune diseases or disorders; dietary and nutritional supplements for medical use; dietary supplements for treating fatigue or liver support; animal feed additive for use as a nutritional supplement for medical purposes; dietary supplements for human consumption or for animals; nutritional additives in the nature of a dietary supplement for medical purposes for use in foods for human consumption or for animals; animal feed supplements; dietary pet supplements in the form of pet treats; fungi preparations for medical or veterinary use for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; pharmaceutical preparations and substances for veterinary purposes for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; chemical preparations for medicinal purposes for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; cardiovascular pharmaceuticals; cardiovascular treatment preparations; pharmaceuticals preparations for the treatment of kidney diseases
Publications
History of USPTO decisions and trademark events.
39 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
05/17/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/17/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/17/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
02/02/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
04/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/23/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/23/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/23/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/23/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/01/2019
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/01/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/01/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/12/2019
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/12/2019
E815
TEAS SECTION 8 & 15 RECEIVED
10/28/2019
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/08/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/08/2014
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/05/2014
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
03/04/2014
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/25/2014
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/24/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/17/2014
IUAF
USE AMENDMENT FILED
01/21/2014
EISU
TEAS STATEMENT OF USE RECEIVED
01/21/2014
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/30/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/04/2013
PUBO
PUBLISHED FOR OPPOSITION
06/04/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/15/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/01/2013
ALIE
ASSIGNED TO LIE
04/20/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/01/2013
XAEC
EXAMINER'S AMENDMENT ENTERED
03/14/2013
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/14/2013
GNEA
EXAMINERS AMENDMENT E-MAILED
03/14/2013
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/14/2013
DOCK
ASSIGNED TO EXAMINER
03/12/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/21/2012
NWAP
NEW APPLICATION ENTERED
11/19/2012
Continuous trademark protection
Get notified about every new filing that threatens LIVERTY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.